Teva Pharmaceutical Industries (TEVA) Capital Expenditures (2017 - 2025)
Historic Capital Expenditures for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to -$860.0 million.
- Teva Pharmaceutical Industries' Capital Expenditures rose 80.74% to -$860.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$501.0 million, marking a year-over-year decrease of 60.24%. This contributed to the annual value of -$501.0 million for FY2025, which is 60.24% down from last year.
- Teva Pharmaceutical Industries' Capital Expenditures amounted to -$860.0 million in Q4 2025, which was up 80.74% from $136.0 million recorded in Q3 2025.
- In the past 5 years, Teva Pharmaceutical Industries' Capital Expenditures registered a high of $157.0 million during Q1 2022, and its lowest value of -$933.0 million during Q4 2023.
- Its 5-year average for Capital Expenditures is -$20.8 million, with a median of $127.0 million in 2022.
- The largest annual percentage gain for Teva Pharmaceutical Industries' Capital Expenditures in the last 5 years was 2213.11% (2023), contrasted with its biggest fall of 75704.23% (2023).
- Teva Pharmaceutical Industries' Capital Expenditures (Quarter) stood at $153.0 million in 2021, then fell by 7.19% to $142.0 million in 2022, then crashed by 757.04% to -$933.0 million in 2023, then grew by 7.07% to -$867.0 million in 2024, then increased by 0.81% to -$860.0 million in 2025.
- Its Capital Expenditures stands at -$860.0 million for Q4 2025, versus $136.0 million for Q3 2025 and $96.0 million for Q2 2025.